Human viral diseases: what is next for antiviral drug discovery?

被引：29

作者：

De Clercq, Erik ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

CURRENT OPINION IN VIROLOGY | 2012年 / 2卷 / 05期

关键词：

VARICELLA-ZOSTER-VIRUS; HELICASE-PRIMASE INHIBITOR; ACTING NEURAMINIDASE INHIBITOR; VITRO ANTIINFLUENZA VIRUS; SMALL-MOLECULE INHIBITOR; CHRONIC HEPATITIS-C; IN-VITRO; BIOLOGICAL EVALUATION; SELECTIVE-INHIBITION; INFLUENZA-VIRUS;

D O I：

10.1016/j.coviro.2012.07.004

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

For the treatment of human immunodeficiency virus (HIV) infections for which there are ample drugs available, the immediate future lies in a once-daily combination pill containing three or four active ingredients. This strategy may also be envisaged for the treatment of hepatitis C virus (HCV) infections as soon as we have at hand the appropriate direct-acting antiviral agents (DAAs) to be combined. A combination drug therapy is generally not entertained for other viruses. Yet, new drugs are at the horizon for the treatment of herpes simplex virus (HSV), varicella-zoster virus (VZV), poxvirus, hepatitis B virus (HBV), influenza and enveloped viruses-at-large.

引用

页码：572 / 579

页数：8

共 104 条

[11]

[Anonymous], 25 INT C ANT RES ICA

[12] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].

Bacon, Bruce R. ;

Gordon, Stuart C. ;

Lawitz, Eric ;

Marcellin, Patrick ;

Vierling, John M. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Boparai, Navdeep ;

Burroughs, Margaret ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Esteban, Rafael .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217

[13] Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence [J].

Baernighausen, Till ;

Tanser, Frank ;

Dabis, Francois ;

Newell, Marie-Louise .

CURRENT OPINION IN HIV AND AIDS, 2012, 7 (02) :140-150

[14] Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice [J].

Berhanu, Aklile ;

King, David S. ;

Mosier, Stacie ;

Jordan, Robert ;

Jones, Kevin F. ;

Hruby, Dennis E. ;

Grosenbach, Douglas W. .

VACCINE, 2010, 29 (02) :289-303

[15] ST-246 Inhibits In Vivo Poxvirus Dissemination, Virus Shedding, and Systemic Disease Manifestation [J].

Berhanu, Aklile ;

King, David S. ;

Mosier, Stacie ;

Jordan, Robert ;

Jones, Kevin F. ;

Hruby, Dennis E. ;

Grosenbach, Douglas W. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (12) :4999-5009

[16] Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293 [J].

Betz, UAK ;

Fischer, R ;

Kleymann, G ;

Hendrix, M ;

Rübsamen-Waigmann, H .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1766-1772

[17] The Emergency Use Authorization of Peramivir for Treatment of 2009 H1N1 Influenza [J].

Birnkrant, Debra ;

Cox, Edward .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (23) :2204-2207

[18] Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency 2 of 10 recent clinical isolates of HSV-1 [J].

Biswas, Subhajit ;

Smith, Christopher ;

Field, Hugh J. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (02) :274-279

[19] The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1 [J].

Biswas, Subhajit ;

Jennens, Lyn ;

Field, Hugh J. .

ANTIVIRAL RESEARCH, 2007, 75 (01) :30-35

[20]

Biswas Subhajit, 2008, Antiviral Chemistry & Chemotherapy, V19, P1

← 1 2 3 4 5 6 7 8 9 10 →